Comparing the effectiveness of four transdiagnostic among adults and adolescences

Comparing the effectiveness of four transdiagnostic treatments on reduction of symptoms of emotional disorders and Cluster B personality disorders among adults and adolescences

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231106059970N1

Enrollment

360

Registered

2023-11-19

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Individuals who meet the full criteria of emotional disorders including mood disorders, anxiety disorders, OCD, PTSD,and eating disorder. Condition 2: Individuals who meet the full criteria of emotional disorders including mood disorders, anxiety disorders, OCD, PTSD, and eating disorders. Condition 3: Individuals who meet the full criteria of emotional disorders including mood disorders, anxiety disorders, OCD, PTSD, and eating disorders. Condition 4: Individuals who meet the fu

Interventions

Intervention 1: Intervention group: Adaptation of Unified protocol for adolescents which consists 8 - 15weekly45-60 minutes session. Primary care-giver can participate in this treatment weekly either

Eligibility

Sex/Gender

All

Age

11 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age between 11-18 in adolescence sample Age between 18 to 65 in adults group Be able to read and speak Farsi fluently, participant in in-person psychotherapy sessions Adolescence sample meet full criteria for at least one emotional disorders In Adult sample: meet full criteria for at least one emotional disorders and /or cluster B personality disorders

Exclusion criteria

Exclusion criteria: active suicidal plan substance dependency, meet criteria as schizophrenia and neurological diseases psychiatry medicines miss more than three psychotherapy session repeatedly

Design outcomes

Primary

Measure	Time frame
Scores of Beck's Depression Inventory (BDI-II). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: Beck's Depression Inventory (BDI-II).;Scores of Beck's anxiety Inventory (BAI). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: Beck's anxiety Inventory (BAI).;Scores of the Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004).;Scores of the Positive and Negative Affect Schedule (PANAS). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: The Positive and Negative Affect Schedule (PANAS) (Watson, Clark, & Tellegen, 1988).	—

Measure

Time frame

Scores of Beck's Depression Inventory (BDI-II). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: Beck's Depression Inventory (BDI-II).;Scores of Beck's anxiety Inventory (BAI). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: Beck's anxiety Inventory (BAI).;Scores of the Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004).;Scores of the Positive and Negative Affect Schedule (PANAS). Timepoint: questionnaires will be assessed at baseline, post-treatment, 6,12,18,24 and 36-month follow-up. Method of measurement: The Positive and Negative Affect Schedule (PANAS) (Watson, Clark, & Tellegen, 1988).

—

Secondary

Measure	Time frame
Scores of Shame severity. Timepoint: baseline, post- treatment, 6,12,18,24 and 36 months follow-up. Method of measurement: The Experience of Shame Scale (ESS, Andrews et al, 2002).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBanafsheh Mohajerin

Shahid Beheshti University of Medical Sciences

banafshehmohajerin@gmail.com+98 912 578 6918

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026